Videos

Expanding Genetic Associations Between Races and Alzheimer Disease: Margaret Pericak-Vance, PhD

Experts discuss the benefits of complement inhibitors in reducing symptoms of myasthenia gravis.

Margaret Pericak-Vance, PhD

July 18th 2022

Technological Advancements Improving, Expanding Capabilities of Antibody Testing: Sean Pittock, MD

The director of the John P. Hussman Institute for Human Genomics at the University of Miami discussed non-APOE–related genetic correlations between different groups of individuals and Alzheimer disease. [WATCH TIME: 5 minutes]

Sean Pittock, MD

July 17th 2022

Apitegromab Continues Positive Efficacy in SMA, Alzheimer Disease Risk Reduced Through Lifestyle Factors, Depressive Trajectories Predict Stroke Risk

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the technological capabilities the center has, including the improved use of neural antibody testing. [WATCH TIME: 6 minutes]

NeurologyLive® Staff

July 16th 2022

The Role of Genetics in Alzheimer Drug Development: Margaret Pericak-Vance, PhD

Neurology News Network for the week ending July 16, 2022. [WATCH TIME: 4 minutes]

Margaret Pericak-Vance, PhD

July 15th 2022

Patient Journey to LGS Diagnosis

The director of the John P. Hussman Institute for Human Genomics at the University of Miami provided insight on the outlook on genetics and gene-based therapies for Alzheimer disease. [WATCH TIME: 3 minutes]

Joseph Sullivan, MD;Kelly Knupp, MD;Mary Anne Meskis;Tracy Dixon-Salazar, PhD

July 15th 2022

Differential Diagnosis for LGS and Challenges in Managing Seizures

Tracy Dixon-Salazar, PhD, reflects on her daughter’s journey to diagnosis of Lennox-Gastaut Syndrome and the impact of the disease on caregivers.

Joseph Sullivan, MD;Kelly Knupp, MD;Mary Anne Meskis;Tracy Dixon-Salazar, PhD

July 15th 2022

Clinical Implications and Patient Education Surrounding the Link Between Epstein-Barr Virus and Multiple Sclerosis

Tracy Dixon-Salazar, PhD, and Kelly Knupp, MD, emphasize key identifiers for the diagnosis of Lennox-Gastaut Syndrome and challenges in managing seizures in these patients.

Scott Newsome, DO, MSCS, FAAN;Lawrence Steinman, MD;Ahmed Obeidat, MD, PhD;Amit Bar-Or, MD, FRCPC;Bridget A. Bagert, MD, MPH

Investigations Into the Causal Link Between EBV and MS

Bridget A. Bagert, MD, and Ahmed Obeidat, MD, PhD, examine the clinical implications of a causal link between Epstein-Barr virus and multiple sclerosis and provide insight on how to discuss this link with patients.

Scott Newsome, DO, MSCS, FAAN;Lawrence Steinman, MD;Ahmed Obeidat, MD, PhD;Amit Bar-Or, MD, FRCPC;Bridget A. Bagert, MD, MPH

Realistic Expectations and Limitations in MS Rehab With Exoskeletons: Francois Bethoux, MD

Lawrence Steinman, MD, discusses his recent publication, which demonstrated the causal link between Epstein-Barr virus and multiple sclerosis, highlighting key findings and conclusions.

Francois Bethoux, MD

Drawing From Experience When Treating Parkinson Disease: Temitope Lawal, MD

The chair of Cleveland Clinic’s Department of Physical Medicine discussed the different ways a newly approved robotic exoskeleton can improve gait in patients with multiple sclerosis. [WATCH TIME: 4 minutes]

Temitope Lawal, MD

Awareness and Diagnosis of Migraine in Primary Care Clinics

The neurologist and movement disorders fellow at University Hospitals Cleveland Medical Center spoke about how his experience as a caregiver shapes his perspective as a doctor in care for those with movement disorders. [WATCH TIME: 3 minutes]

Kita Williams, MD

Migraine Overview and Evaluation

Dr Williams talks about the journey of a typical patient and awareness and diagnosis of migraine symptoms in primary care settings.

Kita Williams, MD

The Importance of Shared Decision-making and Goal Setting in Patients With Myasthenia Gravis

A migraine specialist, Dr Kita Williams, provides an overview of migraine and her approach to evaluating patients with headache.

Ericka Wong, MD

Pharmacological and Nonpharmacological Options for Myasthenia Gravis

Ericka Wong, MD, discusses the importance of shared decision-making and goal setting when treating a patient with myasthenia gravis.

Ericka Wong, MD

Clinical Trial Considerations for Ethnically Diverse, Underrepresented MS Patients

Expert neurologist discusses pharmacological and nonpharmacological options in the treatment of myasthenia gravis.

Jeffrey Dunn, MD;Regina Berkovich, MD, PhD

Postpartum Relapse in Patients With MS

Experts in neurology explore the awareness of multiple sclerosis in ethnically diverse and underrepresented patient populations, commenting on the need for greater clinical trial inclusion.

Jeffrey Dunn, MD;Regina Berkovich, MD, PhD

Emerging Therapies and Future Directions for RRMS

Jeffrey Dunn, MD, and Regina Berkovich, MD, PhD, discuss rates of postpartum relapse in patients with multiple sclerosis and how they approach this topic with their patients.

Heidi Crayton, MD

Impact of Vaccinations on Immunosuppressive Therapy Efficacy

Heidi Crayton, MD, expresses her optimism for the future of multiple sclerosis and highlights emerging therapies and their impact on the care of patients with multiple sclerosis.

Heidi Crayton, MD

Brain Health Assessment Challenges in MS

Dr Heidi Crayton reviews the potential impact of vaccinations on immunosuppressive disease-modifying therapy efficacy in patients with multiple sclerosis.

Stephen Krieger, MD;Heidi Crayton, MD;Jacqueline Nicholas, MD, MPH;Flavia Nelson, MD

The Role of Imaging in the Assessment of Brain Health and Cognition

Jacqueline Nicholas, MD, provides insight into challenges inherent to the assessment of brain health in patients with multiple sclerosis [MS].

Stephen Krieger, MD;Heidi Crayton, MD;Jacqueline Nicholas, MD, MPH;Flavia Nelson, MD

State of Migraine Care and Therapeutics: Richard B. Lipton, MD

Heidi Crayton, MD, shares a patient story to highlight the importance of imaging modalities in identifying brain loss and atrophy in patients with multiple sclerosis [MS].

Richard B. Lipton, MD

Working With Interdisciplinary Teams in Movement Disorders: Temitope Lawal, MD

The director of the Montefiore Headache Center provided an overview of the recent advances in migraine medications and how it has translated to improved care. [WATCH TIME: 2 minutes]

Temitope Lawal, MD

July 12th 2022

Peers & Perspectives: The Induction vs Escalation Approach to MS and the TREAT-MS Trial

The neurologist and movement disorders fellow at University Hospitals Cleveland Medical Center shared his experiences engaging with a diverse community of clinicians at the ATMRD Congress and in clinical practice. [WATCH TIME: 2 minutes]

Scott Newsome, DO, MSCS, FAAN;Ellen Mowry, MD

July 12th 2022

Recently FDA Approved Medications for Myasthenia Gravis

Scott Newsome, DO, and Ellen Mowry, MD, discuss the ongoing TREAT-MS trial and its goals, the importance of the findings for clinical practice in multiple sclerosis, and the ongoing discussion around induction vs escalation in MS treatment. [WATCH TIME: 24 minutes]

James F. Howard Jr., MD;Nicholas J. Silvestri, MD, FAAN

July 11th 2022

Non-Pharmacological Approaches for to Myasthenia Gravis

James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN, review the role of complement inhibitors and FcRn inhibitors in the management of myasthenia gravis.

James F. Howard Jr., MD;Nicholas J. Silvestri, MD, FAAN

July 11th 2022

Advantages in Adding Intranasal Zavagepant to the Migraine Treatment Landscape: Richard B. Lipton, MD

Thought leaders review the role of non-pharmacological strategies to manage myasthenia gravis comorbidities.

Richard B. Lipton, MD

July 11th 2022

Efficacy, Safety of Rimegepant When Used Both as Preventively and As-Need: Richard B. Lipton, MD

The director of the Montefiore Headache Center provided commentary on how analyses presented at AHS 2022 further support the benefits intranasal zavagepant bring to the migraine treatment landscape. [WATCH TIME: 5 minutes]

Richard B. Lipton, MD

July 10th 2022